Abstract
The insulin-like growth factor (IGF) family and the IGF-1 receptor (IGF-1R) play an important role in cancer. This intricate and complex signaling pathway provides many opportunities for therapeutic intervention, and several novel therapeutics aimed at the IGF-1R, particularly monoclonal antibodies and small molecule tyrosine kinase inhibitors, are under clinical investigation. This article provides a patent overview of the IGF signaling pathway and its complexity, addresses the justification for the use of IGF-1R-targeted therapy, and reviews the results of in vivo and in vitro novel therapeutics. Over the past year, the completion of several phase I, II, and III trials have provided interesting new information about the clinical activity of these novel compounds, particularly CP-751,871, IMC-A12, R1507, AMG-479, AVE-1642, MK-0646, XL-228, OSI-906, and BMS-754807. We review the important preliminary results from clinical trials with these compounds and conclude with a discussion about future therapeutic efforts.
Keywords: Cancer, clinical trials, insulin-like growth factor, insulin receptor, IGF-1R, IGF-1R inhibitor, monoclonal antibody, targeted therapy, tyrosine kinase inhibitor, cell cycle
Recent Patents on Anti-Cancer Drug Discovery
Title: Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Volume: 7 Issue: 1
Author(s): Erin R. King and Kwong-Kwok Wong
Affiliation:
Keywords: Cancer, clinical trials, insulin-like growth factor, insulin receptor, IGF-1R, IGF-1R inhibitor, monoclonal antibody, targeted therapy, tyrosine kinase inhibitor, cell cycle
Abstract: The insulin-like growth factor (IGF) family and the IGF-1 receptor (IGF-1R) play an important role in cancer. This intricate and complex signaling pathway provides many opportunities for therapeutic intervention, and several novel therapeutics aimed at the IGF-1R, particularly monoclonal antibodies and small molecule tyrosine kinase inhibitors, are under clinical investigation. This article provides a patent overview of the IGF signaling pathway and its complexity, addresses the justification for the use of IGF-1R-targeted therapy, and reviews the results of in vivo and in vitro novel therapeutics. Over the past year, the completion of several phase I, II, and III trials have provided interesting new information about the clinical activity of these novel compounds, particularly CP-751,871, IMC-A12, R1507, AMG-479, AVE-1642, MK-0646, XL-228, OSI-906, and BMS-754807. We review the important preliminary results from clinical trials with these compounds and conclude with a discussion about future therapeutic efforts.
Export Options
About this article
Cite this article as:
R. King Erin and Wong Kwong-Kwok, Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (1) . https://dx.doi.org/10.2174/157489212798357930
DOI https://dx.doi.org/10.2174/157489212798357930 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Negative Glucocorticoid Receptor Response Elements and their Role in Glucocorticoid Action
Current Pharmaceutical Design Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks
Recent Patents on Anti-Cancer Drug Discovery Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design The Challenge of Exploiting ABCG2 in the Clinic
Current Pharmaceutical Biotechnology Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews SNew Trends in the Development of Opioid Peptide Analogues as Advanced Remedies for Pain Relief
Current Topics in Medicinal Chemistry Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics Recent Advances in New Discovered Molecular Targets in Testicular Germ Cell Tumors
Current Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry The Carnitine Transporter Network: Interactions with Drugs
Current Chemical Biology Diagnostic and Management Challenges of Rapid Lung Metastasis of Gestational Trophoblastic Neoplasia after a Non-molar Pregnancy: A Case Report
New Emirates Medical Journal Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Potential of Selected Antioxidants for Influenza Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Role of Imaging in Testicular Cancer
Current Medical Imaging